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The age-adjusted incidence of prostate can-
cer in Japan has increased over the past two 
decades (Center for Cancer Control and 
Information Services 2007). One cause is con-
sidered to be screening for prostate-  specific 
antigen (PSA), but other causes cannot be 
ruled out. The etiology of prostate cancer is 
poorly understood, but established risk fac-
tors include increasing age, African-American 
ethnicity, and a positive family history of 
prostate cancer (Adami 2008). Hormonal fac-
tors may play a role in the etiology of prostate 
cancer, because androgens, particularly testos-
terone and dihydrotestosterone, are essential 
to the normal growth and functioning of the 
prostate (Adami 2008). For this reason, atten-
tion has been focused on the possible role of 
organochlorines, such as dichlorodiphenyl-
trichloroethane (DDT) and polychlorinated 
biphenyls (PCBs), which are endocrine dis-
ruptors that may have adverse effects on the 
male reproductive system (Safe 2000).
Most evidence to date suggests that farm-
ing (Blair et al. 1992; Buxton et al. 1999; 
Cerhan et al. 1998; Dich and Wiklund 1998; 
Fleming et al. 1999; Inskip et al. 1996; Keller 
and Howe 1994; Krstev et al. 1998; Meyer 
et al. 2007; Morrison et al. 1993; Parker 
et al. 1999; Settimi et al. 2001; Sharma-
Wagner et al. 2000; Van Der Gulden and 
Vogelzang 1996; van der Gulden et al. 1995) 
and pesticide application (Dich et al. 1997; 
Fleming et al. 1999) are associated with an 
increased risk or excess incidence and mor-
tality of prostate cancer, although findings 
of reduced or nonexcess risk have also been 
reported (Boers et al. 2005; Fleming et al. 
2003; Fritschi et al. 2007; Zeegers et al. 
2004). Several meta-analyses of prostate 
cancer and occupational pesticide exposure, 
including those in farming (Acquavella 1999; 
Keller-Byrne et al. 1997), any occupation-
related pesticide exposure (Van Maele-Fabry 
and Willems 2003), pesticide application 
(Van Maele-Fabry and Willems 2004), and 
pesticide manufacture (Van Maele-Fabry 
et al. 2006), have reported an increased risk in 
workers engaged in these occupations. Taken 
together, these studies suggest that organo-
chlorine exposure may play an important 
role in the development of prostate cancer. 
However, one study compared the expert-
assessed likelihood of pesticide exposure 
based on detailed, individual-specific ques-
tionnaire and job-specific module interview 
information with reported farm-related job 
titles as a surrogate for pesticide exposure. 
The authors reported that farming job title 
alone is a poor indicator of the likelihood of 
pesticide exposure, as classification of all farm 
jobs as pesticide exposed is likely to substan-
tially overestimate the number of individuals 
exposed (Macfarlane et al. 2009). On this 
basis, exposure assessment in some studies 
may have been insufficient. Moreover, few 
studies have used biological samples (Hardell 
et al. 2006; Ritchie et al. 2003, 2005) or 
investigated the association between prostate 
cancer and specific organochlorines (Alavanja 
et al. 2003; Charles et al. 2003; Prince et al. 
2006; Settimi et al. 2003). Evaluation of 
blood levels of individual organochlorines 
should therefore provide new information on 
their association with prostate cancer.
In Japan, although the use of organo-
chlorine compounds was banned in the first 
half of the 1970s, their long half-lives have 
resulted in the identification of residues in 
several foods and an ongoing presence in the 
blood or breast milk (Hanaoka et al. 2002; 
Konishi et al. 2001b; Lordo et al. 1996). 
Nevertheless, the association between organo-
chlorines and prostate cancer in the general 
population is not clearly understood.
In this study, we investigated the associa-
tion between plasma organochlorine level and 
prostate cancer in a nested case–control study 
within a large prospective cohort study.
Materials and Methods
Study population. The Japan Public Health 
Center–based Prospective (JPHC) Study was 
initiated in 1990 for cohort I and in 1993 
for cohort II. Cohort I consisted of five pub-
lic health center (PHC) areas (Iwate, Akita, 
Nagano, Okinawa, and Tokyo) and cohort 
II included six PHC areas (Ibaraki, Niigata, 
Kochi, Nagasaki, Okinawa, and Osaka) in 
Japan. The study design has been described in 
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Ba c k g r o u n d: Although accumulating evidence suggests that exposure to organochlorine pesticides 
and polychlorinated biphenyls (PCBs) may contribute to the development of prostate cancer, few 
investigations have used biological samples to classify exposure to specific organochlorines. To our 
knowledge, this is the first prospective study to investigate the association between blood levels of 
organochlorines and prostate cancer risk.
Me t h o d s : We conducted a nested case–control study using data from the Japan Public Health 
Center–based Prospective (JPHC) Study. A total of 14,203 men 40–69 years old who returned the 
baseline questionnaire and who provided blood samples were followed from 1990 to 2005. Using a 
mean follow-up period of 12.8 years, we identified 201 participants who were newly diagnosed with 
prostate cancer. Two matched controls for each case were selected from the cohort. We used a con-
ditional logistic regression model to estimate the odds ratios (ORs) and 95% confidence intervals 
(CIs) for prostate cancer in relation to plasma levels of nine organochlorines: PCBs, dichlorodiphe-
nyltrichloroethane (DDT), hexachlorobenzene (HCB), β-hexachlorocyclohexane (β-HCH), trans- 
and cis-nonachlor, oxychlordane, and mirex.
re s u l t s: No statistically significant association with total prostate cancer was seen for any plasma 
organochlorine, although we did observe an insignificant inverse association for plasma HCB and 
β-HCH. Total PCB in plasma was also inversely associated with advanced prostate cancer but with-
out statistical significance.
co n c l u s i o n: Our results suggest that no overall association exists between prostate cancer and 
organochlorines at the levels measured in our study population.
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detail elsewhere (Tsugane and Sobue 2001). 
The study population was defined as all resi-
dents 40–59 years old in cohort I and 40–69 
years old in cohort II at the start of the respec-
tive baseline survey.
In the present analysis, we excluded the 
Tokyo subjects from the analyses because 
data on cancer incidence were not available. 
Thus, after the exclusion of ineligible sub-
jects (n = 144), we had identified a popula-
tion-based cohort of 65,657 men. Informed 
consent was obtained from each participant 
implicitly when they completed the base-
line questionnaire in which the purpose of 
the study and the follow-up methods were 
described. This study was approved by the 
Institutional Review Board of the National 
Cancer Center, Tokyo, Japan.
Questionnaire survey. A baseline self-
administered questionnaire survey was con-
ducted in 1990–1994. The questionnaire was 
distributed mostly by hand and partly by mail, 
and incomplete answers were supplemented 
by telephone interview. A total of 50,435 men 
(response rate 77%) returned the question-
naire, which included smoking and drinking 
habits, current height (whole centimeters), 
body weight (kilograms), occupation, personal 
and family medical history, and diet. The 
questionnaire inquired about a medical history 
of cancer, cardiovascular disease, diabetes mel-
litus, and other diseases (Konishi et al. 2001a). 
For dietary assessment, we used data from the 
validated food frequency questionnaires found 
in the baseline survey for cohorts I and II, 
which included 44 and 52 food items, respec-
tively (Tsubono et al. 1996).
Blood collection. Subjects voluntarily pro-
vided 10 mL of blood during health checkups 
in 1990–1995. Blood samples were divided 
into plasma and buffy layers and preserved at 
–80°C until analysis. Among respondents to 
the baseline questionnaire, a total of 14,203 
men (28%) donated blood.
Follow-up. Subjects were followed from 
the baseline survey until 31 December 2005. 
Changes in residence status, including the resi-
dence status of participants who were still living, 
were identified annually through the residential 
registry in their PHC area. Of the study sub-
jects, 749 (5.3%) moved out of the study area, 
and 28 (0.2%) were lost to follow-up.
Selection of cases and controls. Study staff 
identified incidence data on prostate cancer by 
using spontaneous reporting from major local 
hospitals in the study area to ascertain cases and 
by linking data from population-based cancer 
registries, with permission from the local gov-
ernments responsible for the registries. Death 
certificates were used to supplement the infor-
mation on cancer incidence. Cases were coded 
using the International Classification of Diseases 
for Oncology (World Health Organization 
2000). Up to the end of the study period after 
blood collection, we identified 201 newly diag-
nosed prostate cancer cases among 14,203 men 
who returned the baseline questionnaire, who 
reported no history of prostate cancer, and who 
provided blood samples. Of these, 97% of cases 
were pathologically confirmed, and 0.5% were 
confirmed by death certificate only. We defined 
advanced cases by a diagnosis of extraprostatic 
or metastatic cancer involving lymph nodes or 
other organs at first diagnosis of prostate cancer. 
If this information was not available, advanced 
cases were defined as those with a high Gleason 
score (8–10) or poor differentiation. These cri-
teria were selected to identify advanced cases 
with a high likelihood of poor prognosis. For 
the remaining cases, the cancer had not metas-
tasized to other organs. We identified a total 
of 48 men with advanced cancer and 144 with 
localized cancer; for 9 (4% of total) cases, the 
cancer stage was   undetermined.
For each case, two controls were selected 
from among subjects with no history of pros-
tate cancer when the case was diagnosed. 
Controls were matched for each case by age 
(within 3 years), PHC area, residence (city 
or town and village), date on which blood 
was obtained (within 60 days), time of day of 
blood collection (within 3 hr), and duration of 
fasting at blood collection (within 3 hr).
Laboratory  assays.  We  measured 
the following plasma organochlorines: 
o,p´-dichloro  diphenyltrichloroethane 
(o,p´-DDT), p,p´-DDT, p,p´-dichloro  diphenyl-
dichloroethylene (p,p´-DDE), hexachloro-
benzene (HCB), β-hexa  chlorocyclohexane 
(β-HCH), trans-nonachlor, cis-nonachlor, oxy-
chlordane, and mirex, and > 41 PCB conge-
ners (International Union of Pure and Applied 
Chemistry numbers 17, 28, 51, 52/69, 43/49, 
48/47, 44, 74, 66, 77, 90/101, 99, 123, 118, 
114, 105, 126, 146, 153, 164/163, 138, 
128/162, 167, 156, 169, 182/187, 183, 174, 
177, 180, 170, 189, 202, 201, 198/199, 196, 
203, 194, 208, 206, and 209). Extraction 
and assay of these compounds from 500 µL 
plasma samples were conducted at Shimadzu 
Techno Research Inc. (Kyoto, Japan) using the 
modified method previously described (Itoh 
et al. 2009). Organochlorines and PCBs were 
detected and measured using a high-resolution 
mass spectrometer (Autospec Ultima, Waters/
Micromass, Manchester, UK) with selected 
ion monitoring connected to a gas chromato-
graph (HP6890, Hewlett Packard, Palo Alto, 
CA, USA) equipped with a capillary column 
(HT8-PCB fused silica capillary column 60 m 
× 0.25 mm i.d. for PCBs; DB-17HT fused 
silica capillary column 30 m × 0.32 mm i.d., 
0.15 µm for the organochlorines) based on 
isotope-dilution mass spectrometry. Limits 
of detection (LODs) were 3.0 pg/g wet for 
organochlorine pesticides and 2 pg/g wet for 
PCB congeners. Measurement values < LODs 
were recorded as zero in this study. When we 
recorded these undetectable values as the LODs 
or as half the LOD values, the results were not 
significantly changed. The sum of PCBs (total 
PCBs) was based on the detectable values only. 
Based on average values for each PCB conge-
ner, total PCBs among control participants 
consisted of the following PCB congeners: 153 
(22.3%), 180 (15.9%), 138 (11.2%), 182/187 
(7.0%), 118 (5.3%), 170 (4.5%), 164/163 
(4.5%), 99 (3.2%), 74 (2.9%), 146 (2.8%), 
194 (2.3%), 198/199 (2.3%), 156 (1.9%), 
183 (1.7%), 48/47 (1.4%), 177 (1.3%), 203 
(1.1%), 105 (1.1%), and the remaining PCBs. 
The remaining PCBs are not shown because 
their values were < 1.0%. Laboratory preci-
sion in this measurement was assessed using 
blank and quality control samples in the same 
batch at each assay. Interbatch coefficients of 
variation ranged between 2% and 8% based 
on 24 replicated measurements of plasma sam-
ples at a mean concentration (picograms per 
gram wet) range of 3.6 (cis-nonachlor) to 688 
(p,p´-DDE). All analyses showed high reliabil-
ity, with an intraclass correlation of > 0.96. 
Table 1. Baseline characteristics of case and matched control subjects at baseline.
Characteristic Cases (n = 201) Controls (n = 402) p-Valuea
Mean age ± SD (years)  58.6 ± 6.4 58.4 ± 6.6 —
Body mass index (kg/m2) (%)
< 18.5 2.5 3.5 0.71
18.5–25 72.6 72.1
≥ 25 24.9 24.4
Smoking status (%)
Never 32.8 27.0 0.07
Former 32.8 32.3
Current 34.4 40.7
Alcohol intake (≥ 1–2 times/week) (%) 69.2 72.4 0.42
Married (%) 93.5 90.6 0.26
Diet (%)
Green tea, daily  81.1 80.4 0.97
Miso soup, daily 82.6 78.9 0.18
Milk, daily 44.3 42.8 0.63
Green vegetables, daily  38.3 28.1 0.07
Fish (≥ 3–4 times/week) 55.2 55.0 0.97
Pork (≥ 3–4 times/week) 27.9 27.6 0.28
ap-Value for Mantel–Haenszel test with matched-pair strata. Plasma organochlorines and prostate cancer risk
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Cases and matched controls were assayed in the 
same batch. All samples were analyzed by labo-
ratory analysts blinded to case–control status.
Total cholesterol and triglycerides were 
enzymatically measured at Kyoto Biken 
Laboratories Inc. (Kyoto, Japan) to examine 
organochlorine levels relative to the amount 
of lipid in plasma. Lipid-adjusted concentra-
tions of organochlorines were calculated by 
dividing plasma organochlorine concentra-
tions by total plasma lipid concentrations. We 
used the method described by Phillips et al. 
(1989) to estimate total plasma lipids.
Statistical analysis. We evaluated baseline 
characteristics and plasma organochlorine   levels 
between cases and controls by the Mantel-
Haenszel test using matched pair strata. Odds 
ratios (ORs) and 95% confidence intervals 
(CIs) for prostate cancer risk were estimated by 
quartile level of plasma organochlorine using a 
conditional logistic regression model. Because 
distributions of all organochlorine concentra-
tions in plasma are positively skewed, the val-
ues were transformed to the log scale. Quartile 
cutoff points were based on the frequency dis-
tribution of controls. Organochlorine levels 
were analyzed using both the crude and lipid-
adjusted plasma values, but because conclusions 
were similar, we show only the results of the 
lipid-adjusted analyses. ORs and 95% CIs were 
adjusted for the following variables as potential 
confounders collected at baseline: smoking sta-
tus (never, former, and current), alcohol intake 
(almost never, 1–3 times/month, ≥ 1 time/
week), body mass index (< 22, 22–23.9, ≥ 24 
kg/m2), marital status (yes/no), intake of miso 
soup (< 3 bowls/week, 1 bowl/day, 2 bowls/
day, ≥ 3 bowls/day), and green tea intake 
(< 1 cup/day, 1–2 cups/day, 3–4 cups/day, 
≥ 5 cups/day). These variables are either known 
or suspected risk factors for cancer or had pre-
viously been associated with the risk of prostate 
cancer (Kurahashi et al. 2007, 2008a). A family 
history of prostate cancer was not evaluated as a 
potential confounding factor because only one 
case subject reported it. Linear trends for OR 
were tested in the conditional logistic regres-
sion model using the median values in each 
category. All p-values are two-sided, and statis-
tical significance was determined at p < 0.05. 
Additionally, we estimated the ORs of prostate 
cases stratified by stage as well as those for all 
cases. All statistical analyses were performed 
with SAS software (version 9.1, SAS Institute, 
Inc., Cary, NC, USA).
Results
Basic characteristics of case subjects and 
matched controls at baseline are shown in 
Table 1. Cases tended to smoke less and to 
consume more green vegetables. The propor-
tion of daily consumers of green tea, miso 
soup, milk, fish, and pork did not differ 
between cases and controls. Although PSA 
screening information was available for only 
78% of cases, the proportion of screening-
  detected cancers was 52.6% (82 cases), of 
which 87.8% (72 cases) were diagnosed as 
localized cases (data not shown).
Table 2 shows that no significant differ-
ences were found between cases and controls 
in median plasma levels of organochlorines. 
p,p´-DDT, p,p´-DDE, HCB, β-HCH, trans-
nonachlor, cis-nonachlor, oxychlordane, and 
mirex were detected in plasma in all subjects, 
but some subjects were < LOD in o,p´-DDT 
and 17 PCB peaks: the percentages of cases 
and controls with levels below the detec-
tion limit were 0% and 0.5% for o,p´-DDT, 
respectively, and from 0.5% for PCB 66 to 
99% for PCB 77, and 0.2% for PCB 90/100 
to 100% for PCB 77, respectively.
Table 3 shows ORs and 95% CIs of total 
prostate cancer risk according to organochlo-
rine levels in plasma. No association between 
plasma levels of any organo  chlorine and total 
prostate cancer was observed, although ORs in 
HCB and β-HCH were below unity, with ORs 
Table 2. Plasma levels of lipid-adjusted plasma organochlorines for case and control subjects.
Cases (n = 201) Controls (n = 402)
Median (IQR) 
(ng/g lipid) < LOD (%)
Median (IQR) 
(ng/g lipid) < LOD (%) p-Valuea
o,p´-DDT 4.3 (2.7–7.4) 0 4.3 (2.5–7.7) 0.5 0.99
p,p´-DDT 40 (26–63) 0 41 (24–64) 0 0.53
p,p´-DDE 910 (560–1600) 0 940 (560–1600) 0 0.38
trans-Nonachlor 71 (51–120) 0 75 (50–120) 0 0.89
cis-Nonachlor 13 (8.9–21) 0 13 (9.1–21) 0 0.92
Oxychlordane 22 (17–36) 0 24 (17–37) 0 0.32
HCB 54 (32–81) 0 55 (34–85) 0 0.70
Mirex 4.2 (3.0–6.1) 0 4.1 (3.1–6.0) 0 0.47
β-HCH 310 (190–480) 0 320 (200–520) 0 0.57
∑PCBs 425 (312–629) 6.9 448 (319–670) 10.2 0.35
PCB 17 0.8 (0.5–1.2) 26.9 0.9 (0.6–1.3) 29.6 0.53
PCB 28 3.0 (2.8–4.8) 0 3.0 (1.9–4.6) 0 0.27
PCB 51 1.5 (1.0–2.3) 47.8 1.5 (0.9–2.6) 45.3 0.80
PCB 52/69 1.1 (0.8–1.8) 2.5 1.2 (0.8–1.9) 2.5 0.72
PCB 43/49 0.6 (0.5–0.9) 35.3 0.7 (0.5–1.0) 38.1 0.59
PCB 48/47 2.4 (0.9–7.7) 0 3.3 (1.0–8.9) 0 0.81
PCB 44 0.5 (0.4–0.9) 27.4 0.6 (0.4–0.7) 32.1 0.15
PCB 74 14 (8.8–20) 0 14 (9.0–22) 0 0.40
PCB 66 2.7 (1.6–4.5) 0.5 2.5 (1.6–4.3) 0 0.12
PCB 77 22 99.0 ND 100.0 N/A
PCB 90/101 2.6 (1.5–4.2) 0 2.7 (1.7–4.3) 0.2 0.81
PCB 99 14 (9.7–22) 0 15 (10–23) 0 0.22
PCB 123 0.5 (0.4–0.8) 50.2 0.6 (0.5–0.9) 54.2 0.62
PCB 118 24 (15–37) 0 23 (15–38) 0 0.43
PCB 114 1.3 (0.9–1.9) 7.0 1.4 (0.9–2.0) 2.2 0.51
PCB 105 5.0 (3.0–7.7) 0 4.7 (3.0–8.0) 0 0.50
PCB 126 0.4 (0.3–0.7) 90.5 0.4 (0.4–0.5) 94.8 0.19
PCB 146 12 (8.5–18) 0 12 (8.9–19) 0 0.41
PCB 153 96 (70–140) 0 99 (72–150) 0 0.33
PCB 164/163 20 (14–28) 0 20 (15–30) 0 0.56
PCB 138 50 (35–75) 0 51 (38–75) 0 0.20
PCB 128/162 0.7 (0.6–1.2) 15.4 0.8 (0.6–1.1) 16.4 0.77
PCB 167 3.5 (2.6–4.8) 0 3.5 (2.4–5.2) 0 0.76
PCB 156 8.5 (6.4–12) 0 8.7 (6.8–12) 0 0.46
PCB 169 0.5 (0.4–0.6) 98.5 0.5 (0.3–0.6) 99.3 N/A
PCB 182/187 28 (19–44) 0 27 (20–44) 0 0.59
PCB 183 7.3 (5.0–11) 0 7.5 (5.3–11) 0 0.39
PCB 174 0.6 (0.5–0.8) 52.7 0.6 (0.5–0.8) 53.2 0.88
PCB 177 5.2 (3.8–7.5) 0 5.3 (3.8–8.6) 0 0.27
PCB 180 62 (41–95) 0 62 (44–96) 0 0.62
PCB 170 19 (13–28) 0 19 (14–28) 0 0.48
PCB 189 1.0 (0.7–1.5) 2.0 1.0 (0.7–1.4) 2.0 0.73
PCB 202 3.0 (2.0–4.9) 0 2.9 (2.1–4.9) 0 0.69
PCB 201 0.6 (0.5–0.9) 39.8 0.6 (0.5–0.9) 36.3 0.87
PCB 198/199 8.9 (5.9–14) 0 8.8 (6.1–14) 0 0.56
PCB 196 3.0 (1.9–4.2) 0 2.9 (2.0–4.8) 0 0.32
PCB 203 4.6 (3.2–7.5) 0 4.6 (3.2–7.6) 0 0.61
PCB 194 8.8 (5.7–15) 0 8.9 (5.9–15) 0 0.53
PCB 208 1.1 (0.7–1.6) 2.0 1.1 (0.8–1.7) 1.2 0.67
PCB 206 2.5 (1.8–3.8) 0 2.5 (1.8–3.9) 0 0.82
PCB 209 1.8 (1.3–2.4) 0 1.8 (1.3–2.4) 0 0.64
LOD, limit of detection; ND, not detectable. Total PCBs were based on the detectable values of the 41 PCBs included here. 
ap-Value for Mantel–Haenszel test with matched-pair strata.Sawada et al.
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for the highest versus lowest quartile of 0.52 
(95% CI, 0.21–1.25; p-trend = 0.11) and 0.56 
(95% CI, 0.30–1.01; p-trend = 0.05), respec-
tively. A significantly decreased relative risk of 
prostate cancer was observed for the second 
quartile group of mirex (OR = 0.54; 95% CI, 
0.30–0.97), but the OR for the highest group 
was above 1. The results were not significantly 
changed when further adjustment was made 
for other potential confounders such as dietary 
intake of milk, vegetables, fish, and meat. 
Further, the results did not substantially change 
when we excluded subjects who provided a 
nonfasting blood sample, that is, within 6 hr 
after a meal. Additionally, no material changes 
were seen when subjects were restricted to those 
without occupational exposure to organochlo-
rines or to those detected by screening, or when 
they were stratified by year of diagnosis (up to 
1997 and 1998 or later).
We next classified the data according to 
prostate cancer stage (Table 4). No significant 
associations were seen between any organo-
chlorine and localized prostate cancer, although 
adjusted ORs in second and third quartile 
groups for o,p´-DDT were insignificantly ele-
vated at 1.79 (95% CI, 0.88–3.65) and 2.01 
(95% CI, 0.96–4.22), respectively. In con-
trast, the OR in the third group for total PCBs 
was significantly decreased for advanced pros-
tate cancer risk at 0.18 (95% CI, 0.04–0.92), 
although the trend was not statistically sig-
nificant (p-trend = 0.17). The other organo-
chlorines showed no statistically significant 
association with advanced prostate cancer.
We also analyzed associations for 41 
individual PCB congeners but found none. 
Moreover, no association was found when the 
PCB congeners were grouped according to the 
method of Wolff et al. (1997) based on struc-
tural and biological activity: no association 
was seen for any group, with ORs (95% CIs) 
for the highest versus lowest quartile of 1.37 
(0.75–2.50) for group 1A, 1.27 (0.63–2.58) 
for group 1B, 1.11 (0.57–2.18) for group 
2A, 1.13 (0.60–2.14) for group 2B, and 1.06 
(0.54–2.09) for group 3 (data not shown).
Discussion
Our results showed that the plasma level of 
organochlorines was not positively associated 
with incident prostate cancer among Japanese 
men. This study, which to our knowledge is 
the first prospective investigation of plasma 
levels of organochlorines and prostate cancer, 
suggests that exposure to organochlorines is 
not associated with prostate cancer in general 
populations.
Many epidemiologic studies have indi-
cated that organochlorine exposure may 
increase the risk or cause an excess incidence 
and mortality of prostate cancer. Several meta-
analyses have reported statistically significant 
associations, with relative risk estimates for 
prostate cancer in farmers versus general pop-
ulations of 1.08 (95% CI, 1.06–1.11) (Blair 
et al. 1992) and 1.12 (95% CI, 1.01–1.24) 
(Keller-Byrne et al. 1997) and in the pres-
ence versus absence of exposure to occupa-
tional pesticide of 1.13 (95% CI, 1.04–1.22) 
(Van Maele-Fabry and Willems 2003), 1.24 
(95% CI, 1.06–1.45) (Van Maele-Fabry 
and Willems 2004), and 1.28 (95% CI, 
1.05–1.58) (Van Maele-Fabry et al. 2006). 
Several experimental findings have shown that 
organochlorine pesticides are endocrine dis-
ruptors that may have adverse effects on the 
male reproductive system (Safe 2000). These 
various findings have led to the hypothesis 
that exposure to some organochlorine com-
pounds may increase risk of prostate cancer. 
Our results do not support this hypothesis, 
however. This discrepancy in results between 
the general population in our study and farm-
ers and pesticide users in several meta-analyses 
may be explained by the following factors. 
First, it is possible that exposure in our study 
population was low relative to exposures in 
other study populations. For example, the 
median value of plasma lipid-adjusted DDE 
among black male farmers in North Carolina 
was higher (1,213 ng/g) (Martin et al. 2002) 
than among those in our populations (910 
ng/g). Even if positive associations between 
organochlorines and prostate cancer do exist, 
the adverse effects may not be apparent at 
low levels. Second, workers who work with 
organochlorines might also be exposed to 
other potential chemicals, such as dioxin, 
which was not measured in our study. In a 
meta-analysis (Van Maele-Fabry et al. 2006), 
workers engaged in manufacturing of phe-
noxy herbicides contaminated with dioxins 
and furans were shown to have an increased 
risk of prostate cancer. Moreover, individu-
als who were exposed to phenoxy herbicides 
contaminated with dioxins in Agent Orange 
had an increased incidence of prostate cancer 
Table 3. ORs and 95% CIs of prostate cancer, by plasma level of lipid-adjusted organochlorine.
Quartile category
Plasma level Low Second Third High p for trend
o,p´-DDT (ng/g lipid) < 2.5 2.5–4.2 4.3–7.6 ≥ 7.7
Cases/controls (n) 43/99 57/99 54/101 47/103
OR (95% CI) 1.00 1.36 (0.81–2.27) 1.27 (0.73–2.20) 1.07 (0.59–1.94) 0.69
ORa (95% CI) 1.00 1.39 (0.79–2.44) 1.29 (0.71–2.34) 1.04 (0.54–2.03) 0.61
p,p´-DDT (ng/g lipid) < 24 24–40 41–63 ≥ 64
Cases/controls (n) 41/94 64/105 50/101 46/102
OR (95% CI) 1.00 1.43 (0.86–2.38) 1.14 (0.67–1.96) 1.02 (0.57–1.83) 0.59
ORa (95% CI) 1.00 1.51 (0.87–2.63) 0.92 (0.50–1.70) 1.00 (0.52–1.92) 0.45
p,p´-DDE (ng/g lipid) < 560 560–939 940–1599 ≥ 1,600
Cases/controls (n) 49/98 52/100 47/94 53/110
OR (95% CI) 1.00 1.04 (0.64–1.69) 1.00 (0.61–1.64) 0.96 (0.58–1.59) 0.79
ORa (95% CI) 1.00 1.00 (0.60–1.66) 0.89 (0.52–1.53) 0.90 (0.52–1.54) 0.65
trans-Nonachlor (ng/g lipid) < 50 50–74 75–119 ≥ 120
Cases/controls (n) 49/96 56/102 44/96 52/108
OR (95% CI) 1.00 1.07 (0.66–1.75) 0.83 (0.47–1.46) 0.83 (0.43–1.62) 0.54
ORa (95% CI) 1.00 1.11 (0.67–1.86) 0.92 (0.49–1.69) 0.86 (0.42–1.78) 0.61
cis-Nonachlor (ng/g lipid) < 9.1 9.1–12.9 13–20.9 ≥ 21
Cases/controls (n) 52/100 48/85 50/111 51/106
OR (95% CI) 1.00 1.07 (0.66–1.73) 0.83 (0.50–1.38) 0.84 (0.45–1.54) 0.54
ORa (95% CI) 1.00 1.13 (0.67–1.89) 0.83 (0.48–1.43) 0.80 (0.41–1.57) 0.46
Oxychlordane (ng/g lipid) < 17 17–23.9 24–36.9 ≥ 37
Cases/controls (n) 46/89 64/107 42/102 49/104
OR (95% CI) 1.00 1.14 (0.69–1.88) 0.75 (0.43–1.30) 0.77 (0.39–1.53) 0.32
ORa (95% CI) 1.00 1.06 (0.61–1.82) 0.74 (0.40–1.36) 0.75 (0.34–1.64) 0.40
HCB (ng/g lipid) < 34 34–54.9 55–84.9 ≥ 85
Cases/controls 54/98 48/102 57/97 42/105
OR (95% CI) 1.00 0.71 (0.37–1.36) 0.78 (0.38–1.62) 0.49 (0.21–1.12) 0.09
ORa (95% CI) 1.00 0.78 (0.38–1.57) 0.86 (0.40–1.88) 0.52 (0.21–1.25) 0.11
Mirex (ng/g lipid) < 3.1 3.1–4.0 4.1–5.9 ≥ 6.0
Cases/controls (n) 57/97 38/104 50/98 56/103
OR (95% CI) 1.00 0.59 (0.34–0.996) 0.84 (0.51–1.39) 0.95 (0.54–1.67) 0.66
ORa (95% CI) 1.00 0.54 (0.30–0.97) 0.85 (0.49–1.46) 1.14 (0.61–2.13) 0.22
β-HCH (ng/g lipid) < 200 200–319 320–519 ≥ 520
Cases/controls (n) 52/99 50/97 56/105 43/101
OR (95% CI) 1.00 0.98 (0.61–1.59) 1.00 (0.62–1.62) 0.78 (0.46–1.33) 0.33
ORa (95% CI) 1.00 0.89 (0.52–1.50) 0.85 (0.50–1.46) 0.56 (0.30–1.01) 0.05
Total PCBs (ng/g lipid) < 319 319–447 448–668 ≥ 669
Cases/controls (n) 67/131 49/89 41/91 44/91
OR (95% CI) 1.00 1.08 (0.66–1.77) 0.86 (0.51–1.44) 0.89 (0.49–1.61) 0.64
ORa (95% CI) 1.00 1.06 (0.63–1.79) 0.84 (0.49–1.46) 0.97 (0.51–1.87) 0.90
aAdjusted for smoking status, alcohol intake, marital status, body mass index, and intake of green tea and miso soup. 
Adjusted ORs were calculated based on subjects with complete information on covariates.Plasma organochlorines and prostate cancer risk
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(Chamie et al. 2008). Third, factors other 
than organochlorines may increase the risk of 
prostate cancer in farmers and workers who 
work with pesticides; for example, lifestyle 
factors such as dietary habits may be unique 
to particular occupations.
With regard to exposure to specific chem-
icals, a significantly increased relative risk 
for DDT was shown in a case–control study 
(Settimi et al. 2003) and in a prospective 
study (Alavanja et al. 2003). Although DDT 
mimics the actions of estrogen by binding to 
estrogen receptors, and p,p´-DDE has been 
demonstrated to be antiandrogenic (Kelce 
et al. 1995), plasma DDT and DDE levels in 
our study were not associated with prostate 
cancer. Meanwhile, exposure to PCB showed 
a positive association with prostate cancer 
mortality in a cohort of workers (Charles 
et al. 2003; Prince et al. 2006), and PCB lev-
els in blood increased risk of prostate cancer 
in three studies (Hardell et al. 2006; Ritchie 
et al. 2003, 2005). In one study using serum 
samples, the multivariate ORs of prostate can-
cer among men with middle concentrations 
of oxychlordane and PCB 180 were more 
than three times those among men with the 
lowest concentrations, without a linear dose 
response (Ritchie et al. 2003). In a further 
analysis in the same data set, a substantially 
greater than doubling of the relative risk of 
prostate cancer was observed among men 
with the highest lipid-unadjusted concentra-
tion of PCBs in group 3 (Wolff’s method) 
compared with those with the lowest con-
centrations (Ritchie et al. 2005). The third 
study, which used adipose tissue, reported 
that PCB 153 in greater than median con-
centrations was positively associated, with OR 
of 3.15 (95% CI, 1.04–9.54) (Hardell et al. 
2006). PCB congeners were classified as estro-
genic, antiestrogenic, or enzyme-inducing 
groups based on structural, biological, and 
pharmacokinetic considerations (Wolff et al. 
1997). Although PCB 153 and 180 are classi-
fied in group 3 and considered to be CYP1A1 
and CYP2B inducers (Wolff et al. 1997), our 
present results showed no positive association 
between prostate cancer and any PCB conge-
ner. The reason for the difference between our 
present findings and these case–control study 
results using biological samples is not clear. 
Given our finding that the association with 
plasma total PCBs tended to differ by stage of 
prostate cancer, one possible reason might be 
differences in the proportion of localized and 
advanced prostate cancer cases among differ-
ent studies. However, this would not explain 
the divergence, because the proportions of 
localized versus advanced prostate cancers in 
our study population was relatively high and 
consistent with those in other highly screened 
populations in which positive associations 
between PCB and prostate cancer have been 
Table 4. ORs and 95% CIs of prostate cancer according to plasma level of lipid-adjusted organochlorines 
by stage.
Quartile category
Organochlorine Low Second Third High p for trend
Localized
o,p´-DDT
Cases/controls 25/66 41/70 44/70 29/72
ORa (95% CI) 1.00 1.79 (0.88–3.65) 2.01 (0.96–4.22) 1.17 (0.50–2.74) 0.59
p,p´-DDT
Cases/controls 30/65 46/71 37/71 26/71
ORa (95% CI) 1.00 1.35 (0.71–2.55) 0.97 (0.49–1.93) 0.65 (0.29–1.46) 0.12
p,p-DDE
Cases/controls 35/67 34/70 48/70 22/71
ORa (95% CI) 1.00 0.86 (0.47–1.59) 1.33 (0.72–2.45) 0.56 (0.27–1.15) 0.14
trans-Nonachlor
Cases/controls 35/67 42/67 28/75 34/69
ORa (95% CI) 1.00 1.18 (0.65–2.14) 0.57 (0.26–1.25) 0.74 (0.29–1.90) 0.65
cis-Nonachlor
Cases/controls 35/69 37/61 34/77 33/71
ORa (95% CI) 1.00 1.22 (0.67–2.24) 0.82 (0.42–1.61) 0.86 (0.38–1.95) 0.65
Oxychlordane
Cases/controls 31/63 48/74 26/71 34/70
ORa (95% CI) 1.00 1.19 (0.62–2.30) 0.70 (0.33–1.46) 0.80 (0.30–2.10) 0.53
HCB
Cases/controls 36/66 29/70 43/71 31/71
ORa (95% CI) 1.00 0.72 (0.28–1.87) 0.97 (0.37–2.53) 0.73 (0.26–2.06) 0.64
Mirex
Cases/controls 33/67 29/66 44/77 33/68
ORa (95% CI) 1.00 0.90 (0.45–1.81) 1.21 (0.63–2.32) 1.27 (0.58–2.78) 0.44
β-HCH
Cases/controls 35/63 32/69 42/75 30/71
ORa (95% CI) 1.00 0.85 (0.44–1.63) 1.10 (0.59–2.06) 0.69 (0.34–1.37) 0.33
∑PCBs
Cases/controls 41/88 33/64 35/63 30/63
ORa (95% CI) 1.00 1.24 (0.66–2.34) 1.33 (0.71–2.50) 1.32 (0.59–2.96) 0.59
Advanced
o,p´-DDT
Cases/controls 10/24 12/25 11/23 11/23
ORa (95% CI) 1.00 0.81 (0.25–2.63) 0.75 (0.18–3.18) 0.96 (0.22–4.26) 0.93
p,p´-DDT
Cases/controls 8/21 12/26 15/23 9/25
ORa (95% CI) 1.00 0.99 (0.27–3.69) 1.42 (0.34–5.99) 0.61 (0.11–3.38) 0.55
p,p´-DDE
Cases/controls 13/23 11/24 5/21 15/27
ORa (95% CI) 1.00 0.98 (0.29–3.36) 0.23 (0.05–1.18) 0.69 (0.19–2.55) 0.64
trans-Nonachlor
Cases/controls 10/23 11/24 9/22 14/26
ORa (95% CI) 1.00 1.12 (0.31–4.10) 1.19 (0.29–4.88) 2.46 (0.44–13.73) 0.28
cis-Nonachlor
Cases/controls 13/24 7/20 10/27 14/24
ORa (95% CI) 1.00 0.48 (0.12–1.85) 0.71 (0.21–2.39) 1.55 (0.34–7.11) 0.43
Oxychlordane
Cases/controls 12/23 11/24 13/24 8/24
ORa (95% CI) 1.00 0.50 (0.13–2.01) 0.78 (0.19–3.27) 0.31 (0.04–2.54) 0.38
HCB
Cases/controls 10/24 11/22 10/25 13/24
ORa (95% CI) 1.00 1.13 (0.24–5.21) 0.53 (0.11–2.43) 0.78 (0.10–6.10) 0.90
Mirex
Cases/controls 14/21 8/27 7/24 15/23
ORa (95% CI) 1.00 0.38 (0.10–1.46) 0.38 (0.10–1.49) 1.60 (0.35–7.23) 0.26
β-HCH
Cases/controls 12/23 14/24 7/24 11/24
ORa (95% CI) 1.00 0.64 (0.19–2.12) 0.35 (0.07–1.69) 0.31 (0.07–1.45) 0.23
∑PCBs
Cases/controls 18/27 9/23 6/22 11/23
ORa (95% CI) 1.00 0.36 (0.09–1.49) 0.18 (0.04–0.92) 0.32 (0.06–1.61) 0.17
aAdjusted for smoking status, alcohol intake, marital status, body mass index, and intake of green tea and miso soup. 
Adjusted ORs were calculated based on subjects with complete information on covariates.Sawada et al.
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reported (Ritchie et al. 2005). The divergence 
between these previous studies and our pres-
ent study might be due to differences in the 
time samples were collected (around 2000 in 
the previous studies vs. around 1990 in our 
study) or age range of subjects (47–85 years 
old in the previous studies vs. 40–69 years old 
in our study), which might have led to differ-
ences in the variation of exposure.
HCB and β-HCH tended to be inversely 
associated with prostate cancer in our study, 
although without statistical significance. We 
also found a lack of association with plasma 
oxychlordane, cis- and trans-nonachlor, and 
mirex levels. In one of the case–control studies, 
high levels of HCB and trans-chlordane in adi-
pose tissue were positively associated with pros-
tate cancer risk (Hardell et al. 2006), whereas in 
an in vitro study, pesticides including β-HCH 
induced the progression of prostate cancer cells 
by activating protein tyrosine kinase (Tessier 
and Matsumura 2001). In contrast, oxychlor-
dane, cis- and trans-nonachlor, β-HCH, and 
mirex exhibited no interaction with the andro-
gen receptor in a reporter gene assay (Schrader 
and Cooke 2000). Results for associations of 
organo  chlorines other than DDT and PCB 
with prostate cancer are therefore inconsistent, 
and further studies are needed.
Given that the majority of studies inves-
tigating the association between organochlo-
rines in blood and breast cancer have shown 
no association, the overall lack of associa-
tion between plasma organochlorines and 
prostate cancer in our study is not surpris-
ing (Itoh et al. 2009; Iwasaki et al. 2008; 
Lopez-Cervantes et al. 2004). Low-level envi-
ronmental organochlorine exposures expe-
rienced by general populations may not be 
associated with an increased risk of cancer. 
Further studies using biological samples are 
required not only in general populations, but 
also for those in specific occupations such 
as farmers, pesticide applicators, and pesti-
cide-manufacturing workers; several previous 
studies have indicated that persons in these 
professions may have an increased risk of pros-
tate cancer (Acquavella 1999; Keller-Byrne 
et al. 1997; Van Maele-Fabry and Willems 
2003, 2004; Van Maele-Fabry et al. 2006).
Several limitations in the interpretation of 
our findings warrant consideration. First, the 
number of prostate cancer cases was relatively 
small, which reflects the low incidence rate 
in Japan (age-standardized rate per 100,000 
world population: 20.7 in 2002) (Matsuda 
et al. 2008). Thus, the power to detect weak 
associations may have been insufficient. 
Nevertheless, our study size is relatively large 
compared with the previous studies that used 
biological samples. Second, our baseline expo-
sure estimates, which occurred at an aver-
age age of 58 years, may not have captured 
etiologically relevant exposure levels if the 
critical window for exposure is early in life. 
Additionally, given that the development of 
prostate cancer is very slow, length of fol-
low-up in this study might have been insuffi-
cient to investigate the association of prostate 
cancer. However, we previously reported a 
statistically significant inverse association 
between plasma isoflavone levels and prostate 
cancer with the same length of follow-up 
(Kurahashi et al. 2008b). Third, although 
selected from the general population, our 
subjects were restricted to those who partici-
pated in the baseline health checkup survey. 
The incidence in this subcohort was therefore 
higher than that in total cohort, and any gen-
eralization of our results should be considered 
with caution (Iwasaki et al. 2006). Several 
strengths also warrant mention. First, blood 
samples were collected prior to the diagnosis 
of cancer in our nested case–control study 
within a population-based prospective study, 
so the results were not affected by patients’ 
recall of exposure. Second, cases and controls 
were selected from the same cohort, thus pre-
cluding the possibility of the selection bias 
inherent to case–control studies.
Conclusion
This study suggests that no overall association 
exists between prostate cancer and organo-
chlorines at the levels measured in our study 
population.
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